The study will evaluate the use of
ECI® in combination with a novel adjuvant to treat bone
cancer in large breed dogs while avoiding amputation.
LENEXA,
Kan., July 31, 2024 /PRNewswire/ -- ELIAS
Animal Health, a clinical stage development company advancing novel
treatments for cancer in companion animals, is preparing to
initiate a new study evaluating the company's adoptive T cell
therapy—the ELIAS Cancer Immunotherapy (ECI®)—in
combination with a novel adjuvant as a limb-sparing treatment for
large-breed dogs suffering from appendicular osteosarcoma. The
study, which will be funded by a grant from Morris Animal
Foundation, will be conducted in collaboration with Dr.
Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri.
Canine bone cancer study to evaluate a new
treatment approach using limb-sparing surgery followed by ECI®
immunotherapy.
"For dogs with appendicular osteosarcoma, amputation of the
affected limb followed by chemotherapy is the typical standard of
care. However, in certain cases amputation may not be appropriate,"
said ELIAS Chief Medical Officer Noe
Reyes, DVM. "In this study, we're evaluating a new approach
where the dog is treated with the limb-sparing surgery followed by
ECI® immunotherapy."
The study will assess the safety and efficacy of the combined
approach in large breed dogs. Dog breeds eligible for the study
include large to giant sized dogs as defined by one of the
following breeds: Saint Bernard,
Mastiffs (all types), Greater Swiss Mountain Dog, Great Dane,
Leonberger, Newfoundland,
Anatolian Shepherd, Rottweiler, Irish Wolfhound, Scottish
Deerhound, Great Pyrenees, Bernese Mountain Dog, Dogue de
Bordeaux, Cane Corso, Boerboel and
Golden Retrievers.
ECI® has demonstrated promising results in previous
canine osteosarcoma studies, and recently achieved a critical
milestone in the product licensure pathway. By combining this
innovative immunotherapy with a novel adjuvant, the study aims to
explore new possibilities for treatments that may not require
amputation, providing hope for a better quality of life for dogs
diagnosed with osteosarcoma.
"Personalized immunotherapy is the greatest advance in cancer in
the 21st century," said Dr. Bryan. "Successfully combining it with
limb-sparing surgery would be a vertical step in osteosarcoma."
Read more about the study from Morris Animal Foundation:
https://www.morrisanimalfoundation.org/article/new-study-aims-revolutionize-osteosarcoma-treatment-giant-dog-breeds
About ELIAS Animal Health
ELIAS Animal Health is a
medical biotechnology company advancing novel targeted T cell-based
and oncolytic immunotherapies for the treatment of canine cancers.
The ELIAS Cancer Immunotherapy (ECI®), a first-in-class
adoptive cell therapy for the treatment of canine cancer, is
available to veterinarians commercially under 9 CFR 103.3 as an
experimental autologous prescription product. The company's novel
therapeutic approach offers the prospect of improved clinical
outcomes and the potential for fundamentally changing the way
cancer is treated. Learn more at www.eliasanimalhealth.com.
Media Contact:
Jessica Wiley
1-816-800-0504
jwiley@eliasah.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elias-animal-health-to-conduct-limb-sparing-canine-osteosarcoma-clinical-study-with-grant-from-morris-animal-foundation-302210521.html
SOURCE ELIAS Animal Health